Public Policy Letters, Statements, Legal Briefs, & Other Responses
-
ACMG Comments on FDA Plausible Mechanism Draft Guidance
-
Letter of Support for FY2027 Funding for NBS Programs
-
Stakeholder Letter Opposing the Patent Eligibility Restoration Act (PERA)
-
Sign-on Letter Urging Reinstatement of the ACHDNC
-
Sign-on Letter to Evicore Regarding Interpretation of NCCN Guidelines
-
Stakeholder Letter Supporting Joint Resolutions to Overturn FDA Rule on LDTs
-
ACMG Response to Senate HELP Committee RFI on Diagnostics Regulation
-
Sign-on Letter Opposing the Patent Eligibility Restoraction Act of 2024
-
ACMG Response to RFI on Gene Therapies Access for Rare Diseases
-
Coalition Letter for NBS Funding in FY 2024 Appropriations